Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29142750
Publication Date : //

Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer.


Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA. A total of 40 age- and sex-matched healthy controls were included in the analysis. The median age of patients was 60 years (range, 24-84 years); the majority of the tumor localization was to the colon (n=81, 58%). The median follow-up time was 14 months, while 43 (31%) patients experienced disease progression and 31 (22%) succumbed to the disease. A total of 81 patients (58%) were in the early stages of disease (stage II and III), and 42% of the patients had stage IV disease. The estimated 2-year overall and 1-year progression-free survival rates for the whole patient group were 70% [95% confidence interval (CI): 58.8-81.2] and 26.2% (95% CI: 12.9-39.5), respectively. The number of patients who received neoadjuvant treatment was 37. Of the patients who were administered palliative treatment, 24 received oxaliplatin, whereas 22 received irinotecan and 9 received fluorouracil/capecitabine. A total of 36 and 15 of the patients who received targeted therapy were administered bevacizumab and cetuximab, respectively. Of the 55 patients with metastatic disease who received palliative chemotherapy (CTx), 31% were CTx-responsive. The baseline median sEGFR levels were significantly higher in patients with CRC compared with the healthy control group (P=0.002). In addition, established clinical variables, including no surgical resection, metastatic stage, higher pathological tumor stage, poorer regression score (3-4) and higher lactate dehydrogenase levels, were found to be associated with higher sEGFR levels (P=0.03, P=0.009, P=0.05, P=0.05 and P=0.05, respectively). The results of the present study did not reveal statistically significant associations between sEGFR concentrations and overall and progression-free survival rates. In conclusion, sEGFR concentrations may be diagnostic markers in patients with CRC; however, their predictive and prognostic values were not determined.

Authors : Karabulut Mehmet , Afsar Cigdem Usul , Alıs Halil , Oran Ebru , Karabulut Senem , Akarsu Cevher , Sahbaz Nuri Alper , Gümüsoglu Alpen Yahya , Bilgin Elif , Aykan Nuri Faruk ,

Related products :

Catalog number Product name Quantity
18-461-10703 Cadherin EGF LAG seven-pass G-type receptor 3 - Flamingo homolog 1; hFmi1; Multiple epidermal growth factor-like domains 2; Epidermal growth factor-like 1 Polyclonal 0.05 ml
18-461-10735 Cadherin EGF LAG seven-pass G-type receptor 3 - Flamingo homolog 1; hFmi1; Multiple epidermal growth factor-like domains 2; Epidermal growth factor-like 1 Polyclonal 0.05 ml
18-461-10733 Cadherin EGF LAG seven-pass G-type receptor 3 - Flamingo homolog 1; hFmi1; Multiple epidermal growth factor-like domains 2; Epidermal growth factor-like 1 Polyclonal 0.05 ml
18-461-10732 Cadherin EGF LAG seven-pass G-type receptor 3 - Flamingo homolog 1; hFmi1; Multiple epidermal growth factor-like domains 2; Epidermal growth factor-like 1 Polyclonal 0.05 ml
18-461-10440 Cadherin EGF LAG seven-pass G-type receptor 3 - Flamingo homolog 1; hFmi1; Multiple epidermal growth factor-like domains 2; Epidermal growth factor-like 1 Polyclonal 0.05 ml
A 1016AG.2 Epidermal Growth Factor-Receptor (EGF-R) antigen: human Epidermal Growth Factor-Receptor 100
A 1016AG.1 Epidermal Growth Factor-Receptor (EGF-R) antigen: human Epidermal Growth Factor-Receptor 10
29-763 EPS8L1 a protein that is related to epidermal growth factor receptor pathway substrate 8 (EPS8), a substrate for the epidermal growth factor receptor. The function of this protein is unknown.This gene 0.1 mg
AK3007.1 Epidermal Growth Factor-Receptor (EGF-R) host: Rabbit; Serum 10
A 3006.2 Epidermal Growth Factor-Receptor (EGF-R) host: Rabbit; Serum 100
A 3006.1 Epidermal Growth Factor-Receptor (EGF-R) Antibody host: Rabbit form: Serum 20
A 3006.2 Epidermal Growth Factor-Receptor (EGF-R) Antibody host: Rabbit form: Serum 100
18-003-43740 Epidermal growth factor receptor kinase substrate 8-like protein 1 - Epidermal growth factor receptor pathway substrate 8-related protein 1; EPS8-like protein 1 Polyclonal 0.1 mg Protein A
ICTS-SER Cancer samples: Colorectal Cancer Serum-Adenocarcinoma Each
orb71570 Epidermal Growth Factor Receptor (985-996) peptide This is Epidermal Growth Factor Receptor (985-996) peptide. For research use only. 1 mg
EIAAB13048 Epidermal growth factor receptor pathway substrate 15-related sequence,Epidermal growth factor receptor substrate 15-like 1,Eps15l1,Eps15R,Eps15R,Eps15-related protein,Eps15-rs,Eps15-rs,Mouse,Mus musc
03-001 Epidermal Growth Factor (EGF), human, active Proteins Cancer Research,Differentiation_Stem Cells 50 ug
03-001-5 Epidermal Growth Factor (EGF), human, active Proteins Cancer Research,Differentiation_Stem Cells 5 x 50 ug
orb61297 Vandetanib Vandetanib is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR). For research use only. 500 mg
EIAAB13303 Epidermal growth factor receptor kinase substrate 8-like protein 3,Epidermal growth factor receptor pathway substrate 8-related protein 3,Eps8l3,EPS8-like protein 3,Eps8r3,EPS8-related protein 3,Mouse
EIAAB13299 Epidermal growth factor receptor kinase substrate 8-like protein 1,Epidermal growth factor receptor pathway substrate 8-related protein 1,Eps8l1,EPS8-like protein 1,Eps8r1,EPS8-related protein 1,Mouse
EIAAB13302 Epidermal growth factor receptor kinase substrate 8-like protein 3,Epidermal growth factor receptor pathway substrate 8-related protein 3,EPS8L3,EPS8-like protein 3,EPS8R3,EPS8-related protein 3,Homo
EIAAB13300 Epidermal growth factor receptor kinase substrate 8-like protein 2,Epidermal growth factor receptor pathway substrate 8-related protein 2,Eps8l2,EPS8-like protein 2,Eps8r2,EPS8-related protein 2,Mouse
EIAAB13298 DRC3,Epidermal growth factor receptor kinase substrate 8-like protein 1,Epidermal growth factor receptor pathway substrate 8-related protein 1,EPS8L1,EPS8-like protein 1,EPS8R1,EPS8-related protein 1,
EIAAB13301 Epidermal growth factor receptor kinase substrate 8-like protein 2,Epidermal growth factor receptor pathway substrate 8-related protein 2,EPS8L2,EPS8-like protein 2,EPS8R2,EPS8-related protein 2,Homo


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur